GlassScriptPhysician profile
Emily Law
NPI 1124532460
$9,265.69
in general payments reported to CMS, 2019-2025
22 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,641 · 2022: $3,634 · 2023: $2,658 · 2024: $1,109 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.14 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,213.62 | 2021-2024 | |
| Amgen INC. | $1,415.65 | 2021-2024 | Evenity, Prolia, Enbrel |
| Novartis Pharmaceuticals Corporation | $1,401.58 | 2021-2025 | |
| Janssen Biotech, INC. | $825.31 | 2021-2024 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $758.48 | 2021-2024 | Cimzia |
| Glaxosmithkline, LLC. | $611.34 | 2021-2024 | Benlysta |
| Pfizer INC. | $358.77 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $320.93 | 2021-2024 | Saphnelo |
| Horizon Therapeutics Plc | $235.01 | 2022-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $232.02 | 2022-2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $191.95 | 2021-2024 | Orencia |
| Lilly USA, LLC | $171.92 | 2022-2024 | Taltz |
| Octapharma USA, INC. | $91.13 | 2022-2023 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $80.23 | 2022-2024 | Tymlos |
| Genzyme Corporation | $77.59 | 2021-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $75.63 | 2022-2024 | Acthar |
| Fresenius Kabi USA, LLC | $59.94 | 2023 | Idacio |
| Alexion Pharmaceuticals, INC. | $37.06 | 2023 | Strensiq |
| Scilex Pharmaceuticals INC. | $35.00 | 2024 | |
| Depuy Synthes Sales INC. | $29.65 | 2022 | |
| Sandoz INC. | $21.70 | 2024 | Hyrimoz |
| Ultragenyx Pharmaceutical INC. | $21.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.